Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4646 - EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide (ENZ) in Combination with Conventional Androgen Deprivation Therapy (ADT) for Hormone Naïve Prostate Cancer (HSPC)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Michael Harrison

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

M.R. Harrison1, P.G. Davis2, M.G. Khouri3, R.T. Gupta4, A.J. Armstrong1, M.A. McNamara5, T. Zhang1, M. Anand6, K. Onyenwoke6, H. Hood6, S. Edwardson7, D. Craig7, Y. Wu8, P. Healy8, B. Coyne9, L. Jones10, D.J. George5

Author affiliations

  • 1 Division Of Medical Oncology, Duke Cancer Center, 27710 - Durham/US
  • 2 Department Of Kinesiology, UNCG, Greensboro/US
  • 3 Division Of Cardiology, Duke Cancer Center, Durham/US
  • 4 Department Of Radiology, Duke Cancer Center, Durham/US
  • 5 Division Of Medical Oncology, Duke Cancer Center, Durham/US
  • 6 Gu Oncology, Duke Cancer Center, Durham/US
  • 7 Health And Fitness Center, Duke University, Durham/US
  • 8 Biostatistics, Duke Cancer Center, Durham/US
  • 9 Cardiac Diagnostic Unit, Duke University Health System, Durham/US
  • 10 Exercise Oncology Research Program, Memorial Sloan Kettering Cancer Center, New York/US
More

Resources

Abstract 4646

Background

ADT is associated with physical side effects and a decline in cardiorespiratory fitness that can be mitigated with exercise (EX). Addition of a more potent androgen receptor inhibitor such as ENZ might worsen these effects. In this pilot study, we investigated whether an EX program could mitigate adverse changes from ADT + ENZ treatment.

Methods

Men starting ADT for M0 HSPC were treated with ADT + ENZ for 8 months and randomized to usual care (UC) or EX for 16 weeks. EX began 4 weeks prior to starting ADT + ENZ and consisted of 48 supervised exercise sessions delivered 3x/week between 55-80% of exercise capacity (VO2peak) for aerobic training and 60-85% of one repetition maximum (1-RM) for resistance training. The primary endpoint was change in VO2peak from baseline to 16 weeks. Secondary endpoints included 6 minute walk distance (6MWD), upper and lower body strength (1-RM), body composition (DXA), and patient reported outcomes (FACT-P, FACIT-Fatigue). The study was originally designed to recruit 56 subjects (N = 28/arm) but was halted early due to funding issues.

Results

26 men (UC, N = 13; EX, N = 13) completed the protocol. Baseline age and BMI (mean ± standard deviation [SD]) were 65.0 ± 8.1 yr and 28.5 ± 4.6 kg/m2. Intention to treat analyses for mean 16-week change from baseline with a 95% confidence interval (CI) for each assessment by arm are presented in the table.Table: 1747P

EndpointUC + ADT + ENZ (mean change [95% CI])EX + ADT + ENZ (mean change [95% CI])
VO2peak (ml kg-1 min-1)-3.2 (-6.3, -0.2)-0.9 (-2.4, 0.5)
6MWD (ft)-32.0 (-71.2, 7.3)+42.0 (5.6, 78.4)
1-RM Leg Press (lbs)+6.7 (-46.7, 60.0)+107.1 (43.2, 171.0)
1-RM Chest Press (lbs)+4.9 (-11.0, 20.9)+24.3 (9.2, 39.4)
1-RM Row (lbs)+3.0 (-10.5, 16.5)+14.9 (0.7, 29.0)
Fat Mass (g)+2949 (565, 5333)-122 (-1593, 1350)
Lean Mass (g)-3088 (-5384, -792)-2094 (-3549, -640)
FACT-P TOI-11.6 (-20.3, -2.9)-5.4 (-10.8, 0.1)
FACIT-F Score-9.2 (-16.0, -2.4)-5.0 (-8.0, -2.1)

Conclusions

Supervised aerobic and resistance EX resulted in less decline in VO2peak, as well as improved function and strength in men treated with ADT + ENZ for M0 HSPC. EX was associated with less fat gain and muscle mass loss, less decline in QOL, and less increase in fatigue. Larger trials of EX in this setting are warranted.

Clinical trial identification

NCT02256111.

Legal entity responsible for the study

Duke University Health System.

Funding

Pfizer (Medivation), Astellas.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.